There have been 68 recent deaths of residents and nurses from the facility in a small New Jersey town.
Category: biotech/medical – Page 2,035
‘DO NOT click the link’; Police warn of scam COVID-19 text messages
Scam alert.
THOMASTON, Me. (WSET) — Police are warning cell phone users of a new text message scam during the coronavirus pandemic. The Thomaston Police Department in Maine posted on Facebook a photo of the alert being sent to people in a text message. The message was sent to someone in Maine from an Indiana area code telling them they need to self-isolate because they came in contact with someone who tested positive or has shown symptoms for coronavirus. The alert also tells you to get tested.
MDMA-Assisted Psychotherapy
Founded in 1986, the Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501©(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS furthers its mission by: Developing psychedelics and marijuana into prescription medicines; Training therapists and working to establish a network of treatment centers; Supporting scientific research into spirituality, creativity, and neuroscience; and educating the public honestly about the risks and benefits of psychedelics and marijuana.
Multiple scientific studies suggest smoking may PROTECT against coronavirus
Another study, by America’s Centers for Disease Control of over 7,000 people who tested positive for coronavirus, found that just 1.3 per cent of them were smokers — against the 14 per cent of all Americans that the CDC says smoke.
The study also found that the smokers stood no greater chance of ending up in hospital or an ICU.
The reasons for this are unclear.
Report: Covid-19 patients recovering quickly after getting experimental drug
Covid-19 patients who are getting an experimental drug called remdesivir have been recovering quickly, with most going home in days, STAT News reported Thursday after it obtained a video of a conversation about the trial.
The patients taking part in a clinical trial of the drug have all had severe respiratory symptoms and fever, but were able to leave the hospital after less than a week of treatment, STAT quoted the doctor leading the trial as saying.
“The best news is that most of our patients have already been discharged, which is great. We’ve only had two patients perish,” Dr. Kathleen Mullane, an infectious disease specialist at the University of Chicago who is leading the clinical trial, said in the video.
Proteins may halt the severe cytokine storms seen in COVID-19 patients
:oooo.
One of the defining features of Covid-19 is the excessive immune response that can occur in severe cases. This burst of immune overreaction, also called a cytokine storm, damages the lungs and can be fatal.
A team of MIT researchers has developed specialized proteins, similar in structure to antibodies, that they believe could soak up these excess cytokines.
“The idea is that they can be injected into the body and bind to the excessive cytokines as generated by the cytokine storm, removing the excessive cytokines and alleviating the symptoms from the infection,” says Rui Qing, an MIT research scientist who is one of the senior authors of the study.
Gilead data suggests coronavirus patients are responding to treatment
A Chicago hospital treating severe COVID19 patients with Gilead Sciences’ antiviral medicine remdesivir in a closely watched clinical trial is seeing rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than a week, STAT has learned.
Remdesivir was one of the first medicines identified as having the potential to impact SARS-CoV-2, the novel coronavirus that causes Covid-19, in lab tests. The entire world has been waiting for results from Gilead’s clinical trials, and positive results would likely lead to fast approvals by the Food and Drug Administration and other regulatory agencies. If safe and effective, it could become the first approved treatment against the disease.
The outcomes in patients at a Chicago hospital offer only a snapshot of remdesivir’s effectiveness, but are the first clinical data to surface to date.